Drug
Edp 305
Edp 305: highest development phase Phase 2, developed by Enanta Pharmaceuticals. 4 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Enanta Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| EDP-305 1.5 mg NCT04378010 | Phase 2 | Non-Alcoholic Steatohepatitis |
| EDP-305 NCT03748628 | Phase 1 | NASH - Nonalcoholic Steatohepatitis |
| EDP 305 NCT03207425 | Phase 1 | NASH |
| EDP 305 NCT02918929 | Phase 1 | Presumptive NAFLD |
Latest
Follow Edp 305 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.